Participated · Series C · Jul 2026

Cyllene Therapeutics (formerly EG 427) develops targeted neurotherapeutics using its proprietary HERMES non-replicating HSV-1 vector platform. Its lead candidate, EG110A, is a DNA medicine being developed for multiple severe bladder diseases, including neurogenic detrusor overactivity (NDO) related to spinal cord injury. Ongoing studies have shown substantial and sustained reductions in urinary incontinence episodes for at least nine months post-treatment in patients with spinal cord injury–related NDO. The company plans a Phase 2b/3 study of EG110A in 2027 and intends to expand into overactive bladder and other neurological indications such as pain and migraine. Cyllene recently completed a €33 million Series C financing to fund these clinical and platform-expansion efforts. The company highlights its position as a leader in non-replicating HSV-1 vector technology in neurology.

Led · Series D · May 2026

Rivermark Medical develops the FloStent, a minimally invasive, fully reversible urethral stent intended as a first-line device therapy for men with urinary symptoms from benign prostatic hyperplasia. The FloStent is designed for outpatient placement during routine cystoscopy using standard urology tools and can be removed or adjusted after implantation to preserve future treatment options. Rivermark reported positive results from a multicenter RAPID II study showing rapid recovery and durable benefit at 24 months. The company is conducting a pivotal RAPID III clinical trial and is pursuing U.S. regulatory approval and commercial launch. Financially, Rivermark raised $20 million in a Series D led by Andera Partners to support the pivotal trial, regulatory submissions, and launch preparations. Aneta Sottil of Andera joined the company’s board as part of the financing. The FloStent is currently an investigational device limited to experimental use under U.S. federal law.

Led · Series A · Mar 2026

Alveus Therapeutics is advancing a pipeline of peptide-based treatments aimed at delivering durable weight loss and improved metabolic control. Its lead candidate, ALV-100, is a bifunctional molecule that combines glucose-dependent insulinotropic polypeptide receptor antagonism with glucagon-like peptide-1 receptor agonism, and is positioned to enter Phase 3 after characterization work funded by the new capital. A second program, ALV-200, is a highly selective amylin receptor 3 agonist, while the company is also progressing an oral amylin program expected to begin first-in-human studies within 18 months. Alveus focuses on therapies with sustained efficacy, improved tolerability, and reduced treatment burden compared with existing obesity drugs. The firm plans to run multiple development programs in parallel over the next 18–24 months to reach key value inflection points, including advancing ALV-100 to a Phase 3-ready state and moving early-stage assets into the clinic. Its recent $197 million Series A financing provides the capital to execute these objectives and expand its investor base.

Participated · Series B · Jan 2026

Founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu, Exciva focuses on therapies for neuropsychiatric symptoms in Alzheimer’s disease dementia and related brain disorders. Its lead candidate, Deraphan, combines two CNS-active compounds designed to reduce agitation in Alzheimer’s patients. The company is currently preparing and financing a Phase 2 clinical study to evaluate Deraphan’s therapeutic potential. Exciva leverages proprietary discovery capabilities to identify synergistic compound combinations addressing unmet neuropsychiatric needs. The latest capital infusion strengthens its balance sheet and extends runway through critical mid-stage clinical development. While the company has not disclosed revenue or patient enrollment numbers, the new financing underscores investor confidence in its scientific approach and market opportunity. The refreshed board now includes representatives from key new and existing investors, ensuring broad strategic guidance as the program advances.

Led · Series A · Jan 2026

Spiro Medical is a venture-backed medical device company based in Irvine, California that is building the first purpose-built Pulmonary Neuromodulation System (PNM) for asthma patients. The proprietary implant targets neural reflex pathways in the lungs with the goal of reducing symptoms such as wheezing, shortness of breath, and coughing. Founded by Stephen Pyles, M.D., Kurt Gehlsen, M.D., Ph.D., Rinda Sama, and G. Jay Jiang, Ph.D., the company enters the market with issued patents and initial human data supporting the technology’s clinical potential. Proceeds from its recent financing will fund final system design, clinical trials, and U.S. regulatory work. Leadership claims deep expertise in implantable neuromodulation, positioning the team to build a “world-class” product. Although the company is pre-revenue, it is targeting a large addressable market of more than 28 million U.S. asthma sufferers and 300 million patients worldwide.